{"name":"Vector Y Therapeutics","slug":"vector-y-therapeutics","ticker":"","exchange":"","domain":"vectory.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Optional Rescue medication - Corticosteroids: Methylprednisolone","genericName":"Optional Rescue medication - Corticosteroids: Methylprednisolone","slug":"optional-rescue-medication-corticosteroids-methylprednisolone","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Optional Rescue medication - Corticosteroids: Methylprednisolone","genericName":"Optional Rescue medication - Corticosteroids: Methylprednisolone","slug":"optional-rescue-medication-corticosteroids-methylprednisolone","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOSmdtaUc5aEczUzVUOHlsY2NXejdyQTBZNzFtTS1QQk1XZGFLUVNLa3Z4VExLQzBGSVUzQ0VBYVU1dmVwcjc4aVBXNW8wTmJiTjR0Q2ZERnp4SzJiZXV4bFRYMTZpdlU2RmZjZW9Ycmdwd1NrMlhzNXJXSXZIUUhlSnZha1VZZjZzaE9GLUNWdGlObkw1a3VpNlhDRms?oc=5","date":"2026-02-23","type":"pipeline","source":"BioSpace","summary":"Historic ALS Investment Signals New Treatment Momentum - BioSpace","headline":"Historic ALS Investment Signals New Treatment Momentum","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxOTE5LOThXaVNWcG1CNV9OdENzVW1LU0pyMndQS2pOdlBSWHV5ZUZUNVlTbGZEenB4M3NJRW5XUXItYU1CbkNBaEdDWEtIZkJCYlNGQ1JiVXpUX2syZXZJNU5YMDNIYTIzeld3WTVrcV9PUElNWkx5ZHFxNUJ4R2owNkZKNndMam02STNkTWFMbFZsUC1yeE1MRFZwTHlXUQ?oc=5","date":"2026-02-12","type":"trial","source":"newswire.com","summary":"Unlearn to Apply AI-Generated Digital Twins to the VectorY Therapeutics PIONEER-ALS Study - newswire.com","headline":"Unlearn to Apply AI-Generated Digital Twins to the VectorY Therapeutics PIONEER-ALS Study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNalB0Wjk2TXdtNWhpQS1XWVpFYkdCazNXOHRSOG9XM29XeFZuNVJiaGRpN0NHeE1IQzZmMnN2UDdCOXFjNUgwaElIall0Z2t6UEx2WFF5eng3MFFMV1hYSUNnS1NGNmRSQXNXQWRlZ3c0b2h3YTRVNHRYb1lvcFg1RnI1TzMxdjZJcXZDT3p3aU85S2RuSUJZSGdOVHMxMVdZdFE?oc=5","date":"2026-02-10","type":"trial","source":"BioPharm International","summary":"VectorY Doses First Patient in TDP-43–Targeting ALS Trial - BioPharm International","headline":"VectorY Doses First Patient in TDP-43–Targeting ALS Trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAJBVV95cUxPVFhuclFOam5KOEg5NGJSc1RITjdfYWZmUUR2dV9xcUJuV0htUVVnem1xWFc5NGFhSXVERmhhakt1c1h2MDFLblZnZWFmT0FSckRJNFhybFplMkdzLTBqdkhub24tNkRrbW8zWHJrdXdURUk3VkFBOU1kUkxKTkd3dG80ODZYWjBkbXdlUG1EazRpTnl5bWJXaHdMTWotckhqVVNPaGFCX1ByTkxaUnVVdEhDSDJibHRVTUlJSmJvWmNmU0JHcllUdnNOaU5manEtUG1xWmhwZXhDVWZZWjYwZkQ5ZjVJZUlHd3U1cksweU92RE5sejZYNUNYX3NZY25lYnBJX0wyQktBZ1NHZzN2enR4bmdWNm5wWWZaQ1daUGhpc3BteGllUTQxcTFSMTVTek1maA?oc=5","date":"2026-02-09","type":"trial","source":"businesswire.com","summary":"VectorY Therapeutics Announces First Participant Dosed in Phase 1/2 PIONEER-ALS Clinical Trial of VTx-002 in People with Amyotrophic Lateral Sclerosis (ALS) - businesswire.com","headline":"VectorY Therapeutics Announces First Participant Dosed in Phase 1/2 PIONEER-ALS Clinical Trial of VTx-002 in People with","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxQOFZhSzdoOF9CQ0tpM0FlS2FWY29DQy04UV92NzE4RHZuQ3FRSHBMTEhhdUx6SWZhNlJYbXRkQ0hROHY5cUpnYWlWM08yYmtOT25odDhaVzZGam93ZUFsRU84VFBndU9MbFZTY3VlRzdHd1Q3MGpWZ2dnOGY0VWdIcUFHOFYxdzlLSHQ4V3lobjdGX2ZGZUtjbGhUNEJRYy1zaDNmZkZFVVFPT0ZNVksydnM0YWR3UGhpVllwQWZOTGg0d0wwbTZZ?oc=5","date":"2026-02-05","type":"pipeline","source":"businesswire.com","summary":"VectorY Therapeutics Appoints Kevin Pojasek, Ph.D., to Board of Directors - businesswire.com","headline":"VectorY Therapeutics Appoints Kevin Pojasek, Ph.D., to Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYkFVX3lxTFA3czdwNmR5WkQ5cHJ5eFkwNEZWYU5OVnBuVlpEcDdRMVF4bmRLbEJfU0NNTFdhczZVeXkyYmEzaHo4czFSNzFuV0ppZE9FdC1BMXpBb3c0RlB3VXV0YXJUOHhR?oc=5","date":"2026-01-19","type":"pipeline","source":"labiotech.eu","summary":"10 promising biotechs racing toward a cure for ALS - labiotech.eu","headline":"10 promising biotechs racing toward a cure for ALS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE56dDFDdXRNQ0s3Y3RuYU05Y3prSDdlTE9fdTJ4RG45Rm1RWXp1T244VVk1MTNNUFhib3RJQWU5R1VjWTlYUkNoQUdxVEtTTVk1ZHpUSTdESS1fTE9rc3ZQdEtoVjB6dTRkUEpBU0ZMRkFpT2d2Q0t2d204bHI?oc=5","date":"2026-01-13","type":"pipeline","source":"labiotech.eu","summary":"Meet 7 biotech companies in the Netherlands changing the game - labiotech.eu","headline":"Meet 7 biotech companies in the Netherlands changing the game","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwJBVV95cUxQcTBJQ2xldjFETTZraXllMGdkN2k2czNmMWNjTzRGa0ctWW9ONXA5Z1ZZU3A4bFhjVHNCekZCU0c5X3pPM2NMT0ZxbnVvZVVjZ3lxUm1DX29xWi10dm1idjUwYmcyUlU3bDA0cFlFNkhXUnJfTGxHWE1oeXpMc2xhQlNoRzQ5SVVRV0ZDbmNaOWFzUm82RnZ1cDVuM2luc1pleFBobTcxVldUWFRERXI3WjdCMG40dXNhemNiYk5vV0Iyc0Nqd25reTZOV0xmM0Nwbm11XzJDNzRaNFJWV3VFSU8yWGNzNnZyanpkTDF3UVNuYTRMMVNXcHNvYWJpcnFKUm5vc0pBU3NKNGhjS2xjSnVoZmFXdXUyQWNxTW5jY25fSVJBeVdfVWc3NWhPMEE?oc=5","date":"2026-01-08","type":"regulatory","source":"businesswire.com","summary":"VectorY Therapeutics Receives FDA Fast Track Designation for VTx-002, a First-in-Class Vectorized Antibody Targeting Underlying Disease Biology in ALS - businesswire.com","headline":"VectorY Therapeutics Receives FDA Fast Track Designation for VTx-002, a First-in-Class Vectorized Antibody Targeting Und","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxNTUs1bUczMG96MDlKSzQ5eDBOTk1qWnRfa180bmUyQXllSUVnRUg2ZldFZzBRT3ZvOUNJMGJqb1o1WGxUTC0wbC1OZXo5SjVlempoZVgyRGh6M3d6X0E5UXdkeXdmRU1YcU5PYnpkclM5aXQtWXBITjRsRjZyZllDelBxZ24?oc=5","date":"2026-01-08","type":"regulatory","source":"Longevity.Technology","summary":"VectorY wins FDA fast track for ALS therapy - Longevity.Technology","headline":"VectorY wins FDA fast track for ALS therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTFBYS0wzR05vVDQwdkpWTWNvNWxyX2RENzRxamdRTnA5d2FHTTJFWVZjTy00X0pmS2ZqUU9hUFhfQVBsUWx0eFRPcXBGZFNsdUJ0OE1rVXlEbkNDXzFWaWJiUU9qT1F2ZHIydDg5SjVlN255QQ?oc=5","date":"2025-12-04","type":"regulatory","source":"Clinical Trials Arena","summary":"FDA clears VectorY’s PIONEER-ALS Phase I/II trial for ALS - Clinical Trials Arena","headline":"FDA clears VectorY’s PIONEER-ALS Phase I/II trial for ALS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxPR3ZQcklRbm1mSmR4OEFhX0c5a2cyOHpGZU1IU3A2YzVjQzh3WF9ELU5RZGFYWF9JcUFySVh1MzFzLUc3Slc0d1VvVGJWcFZiUWdRa25xOW9TRlBsNFVoQzNhMmh5VlVZNkl5T2Z6ZlRFS0lKWVpvSWdqSUpHNjlzUE81SXI?oc=5","date":"2025-12-03","type":"regulatory","source":"pharmaphorum","summary":"FDA clears trial of 'vectorised' ALS antibody from VectorY - pharmaphorum","headline":"FDA clears trial of 'vectorised' ALS antibody from VectorY","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxNY0R4LXRMLWtiWklPMW5CXzdLVXhDUlY5VGJrU0dSc3FQcjYyUmMzSmNfd3U4WDNDNWpvWEQtZ0hBbE9oWDF1MnYyaHMwejBiOWt4U0Y3SS13dnJWZmlrWjhjYlI1STlRTDZfOFdrYWc2MTRZWi1LZEREb3lsWFhDdExFRGJQX1ZMNjBpeGxrUGtCeHI5eEc0LQ?oc=5","date":"2025-12-03","type":"regulatory","source":"Longevity.Technology","summary":"VectorY’s new ALS therapy moves forward after FDA clearance - Longevity.Technology","headline":"VectorY’s new ALS therapy moves forward after FDA clearance","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}